SignalXSignalX

CYTK CYTOKINETICS INC

FY2025 10-K
Filed: Feb 26, 2026
Health Care
Pharmaceutical PreparationsSEC EDGAR
CYTOKINETICS INC Overview

CYTOKINETICS INC (CYTK) filed its fiscal year 2025 10-K annual report with the SEC on Feb 26, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.

AI Filing Analysis
FY2025 10-K

Business Overview

  • • Core business model: biopharmaceutical development and commercialization focused on muscle biology therapeutics for cardiovascular diseases
  • • New product launch: MYQORZO approved by FDA in Dec 2025 for symptomatic oHCM, first commercial sales commenced Q1 2026
+3 more insights

Management Discussion & Analysis

  • • Revenue $88.1M in 2025, up $69.6M from $18.5M in 2024, driven by license and milestone revenues from Bayer and Sanofi
  • • Operating expenses rose sharply: R&D $416.0M (+23% YoY), G&A $284.3M (+32% YoY), reflecting clinical advancement and commercial readiness
+3 more insights

Risk Factors

  • • Cybersecurity risk oversight led by Audit Committee with tech, risk, finance expertise and regular briefings from CISO, CEO, CFO
  • • Dependence on Chief Information Security Officer Eric Brown with 10+ years cybersecurity experience for managing critical security operations
+3 more insights

Financial Summary
XBRL

Revenue

$88M

Net Income

-$785M

Operating Margin

-695.4%

Net Margin

-891.6%

ROE

119.0%

Total Assets

$1.4B

EPS (Diluted)

$-6.54

Operating Cash Flow

-$510M

Source: XBRL data from CYTOKINETICS INC FY2025 10-K filing on SEC EDGAR. All figures in USD.

Get deeper insights on CYTOKINETICS INC

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.

Try Pro free for 1 month!

Enter SX-8KKYTN at checkout

Limited spots available